IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	Data is not available	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	Data is not available	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	Data is not available	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

Data is not available

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

Data is not available

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

Data is not available

2024/12/30

Summary

We are a medical imaging solutions provider, principally engaged in providing medical imaging film products and medical imaging cloud services in Shandong Province. In respect of our medical imaging film products business, our Group engages in the distribution of medical imaging film products from international brands, in particular, the Medical Imaging Products Manufacturer and the sale of our self-branded medical imaging film products. For our distribution business, our Group was the Tier-2 distributor of the Medical Imaging Products Manufacturer in Shandong Province. In respect of our medical imaging cloud services business, our Group was the third largest medical imaging cloud services supplier in Shandong Province with a market share of approximately 4.7% and had a market share of approximately 0.4% in China, in terms of sales revenue in 2021. Our Group plans to focus its business in Shandong Province. We have been the distributor of international medical imaging film products since 2016. Leveraging on our established customer base in the medical imaging market in Shandong Province and with a view to increasing our profitability, we have provided our self-branded medical imaging film products to our customers in Shandong Province since 2018. The sale of the medical imaging film products of the Medical Imaging Products Manufacturer constituted approximately 89%, 76%, 72% and 68% of our revenue under the medical imaging film products business segment during the three years ended 31 December 2021 and the six months ended 30 June 2022 and the sale of medical imaging film products of our own brand constituted approximately 9%, 19%, 28% and 32% of our revenue under the medical imaging film products business segment during the same periods. Except for the minimal revenue generated from the sale of medical imaging film products of another international brand during the two financial years ended 31 December 2020, our Group has only distributed medical imaging film products of the Medical Imaging Products Manufacturer since 2021. Having established a market position in the medical imaging film products market in Shandong Province and by riding on the increasing demand for medical imaging informatisation and medical imaging cloud platform, we tapped into the medical imaging cloud services market by providing hospitals and healthcare institutions with medical imaging cloud services in 2017. With an aim to quickly penetrate into the market, we provide such services in the course of the sale of medical imaging films. Our Directors believe that such services help digitise the medical images and thereby enable medical practitioners and patients to access patients’ information anytime anywhere and increase the efficiency and accuracy of diagnosis and treatment. Our Directors also believe that such a sales model will increase customers stickiness. As at 31 December 2019, 2020 and 2021, 30 June 2022 and as at the Latest Practicable Date, we had 61, 63, 62, 57 and 61 hospitals and/or healthcare institutions customers. Out of the 61, 63, 62, 57 and 61 customers, 42, 51, 53, 53 and 55 customers also subscribed for our medical imaging cloud service for the same year/period. (i) Sale of medical imaging films We engage in the sale of (i) medical imaging films procured from international brands, including the Medical Imaging Products Manufacturer and (ii) medical imaging films under our own ‘‘冠澤慧醫’’ (Guanze Huiyi) brand to hospitals and healthcare institutions. In the course of the sale of medical imaging films, depending on our customers’ needs, we will provide the corresponding self-service film output printer and/or medical image printer to them and our customers are not charged for the corresponding equipment. Occasionally, we also provide medical image data distribution system (including CDs) without charging our customers. Our self-branded medical imaging films are manufactured by OEM manufacturers, and further packaged and labelled by us while our self-branded medical imaging printers are manufactured by OEM manufacturers. (ii) Provision of medical imaging cloud services Further, we will also offer four types of medical imaging cloud services including (i) digital medical imaging cloud storage platform; (ii) digital medical image platform; (iii) regional imaging diagrams platform; and (iv) PACS system, in the course of the sale of medical imaging films. Revenue generated by our products and services During the Track Record Period, the medical imaging film products business segment accounted for the majority of our revenue. For the three years ended 31 December 2021 and the six months ended 30 June 2022, our sale of medical imaging film products accounted for approximately 91.5%, 93.7%, 93.3% and 94.1%, respectively, of our total revenue, and our provision of medical imaging cloud services accounted for approximately 8.5%, 6.3%, 6.7% and 5.9%, respectively, of our total revenue. Source: Guanze Medical (02427) Prospectus (IPO Date : 2022/12/15)
Listing Market	MAIN
Industry	Health Care Services
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Meng Xianzhen (73.74%)
Directors	Meng Xianzhen (Chairman and Chief Executive Officer and Executive Director) Guo Zhenyu (Executive Director) Meng Cathy (Non-Executive Director) Chang Shiwang (Independent Non-Executive Director) Wong Man Hin Raymond (Independent Non-Executive Director) Zhao Bin (Independent Non-Executive Director)
Company Secretary	Zhang Senquan
Principal Bankers	Industrial And Commercial Bank of China
Solicitors	Jingtian & Gongcheng LLP
Auditors	Ernst & Young
Registered Office	Unit A, 16th Floor, Kingswell Commercial Tower, 171 Lockhart Road, Wan Chai, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.guanzegroup.com
Email Address	guanzeshanghai@vip.163.com
Tel No	(86 531) 5816-5902
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates